1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited

6,098.65
INR
+21.75
(+0.36%)
67.85EPS
121.09P/E
205.40BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
189.5
187.62
225.49
217.48
228.4
282.77
332.71
323.42
322.24
401.19
518.21
685.32
909.03
972.86
Basic EPS, GAAP
-0.2
-8.34
2.1
8.02
10.36
21.78
28.88
37.32
24.64
39.72
64.6
46.3
75.01
67.85
Free Cash Flow per Basic Share
-8.98
-27.8
19.18
12.98
1
14.52
29.28
38.83
36.47
19.91
6.84
25.44
-7.5
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
1
2
2
8
16
24
32
- -
Book Value per Share
68.64
60.3
81.4
89.15
98.77
120.32
145.78
182.47
204.56
235.48
284.77
308.14
349.12
- -
Tangible Book Value per Share
68.64
60.3
81.4
89.15
98.77
120.32
145.78
182.47
204.56
235.48
283.92
307.88
349.12
- -
Basic Weighted Avg Shares
25
25
25
25
25
25
25
25
25
25
25
25
25
25
Sales/Revenue/Turnover
4,737
4,690
5,637
5,437
5,710
7,069
8,318
8,086
8,056
10,030
12,955
17,133
22,726
24,321
Operating Margin (%)
-4.84
-4.93
-0.12
5.45
5.98
7.98
12.33
14.38
8.65
14.84
13.23
12.54
10.32
8.74
Depreciation Expense
101
153
174
158
147
149
186
198
170
163
149
400
286
172
Net Income, GAAP
-5
-208
53
201
259
545
722
933
616
993
1,615
1,157
1,875
1,696
Effective Tax Rate (%)
- -
- -
8.76
43.52
40.84
25.07
36.64
26.59
25.82
25.96
26.43
25.98
25.65
25.69
Profit Margin (%)
-0.11
-4.44
0.93
3.69
4.54
7.7
8.68
11.54
7.65
9.9
12.47
6.76
8.25
6.97
Working Capital
311
34
228
612
1,140
1,457
2,151
3,153
3,730
4,515
5,756
6,394
7,581
- -
LT Debt
- -
- -
- -
- -
- -
- -
93
86
50
37
28
295
968
- -
Total Equity
1,716
1,508
2,035
2,229
2,469
3,008
3,644
4,562
5,114
5,887
7,119
7,704
8,728
- -
Return on Invested Capital (%)
- -
- -
-0.33
7.75
7.99
15.52
19.57
20.81
11.01
15.08
21.41
12.53
19.79
- -
Return on Capital (%)
- -
- -
2.97
9.41
11.03
19.88
21.54
22.28
12.61
17.88
24.75
15.34
21.33
- -
Return on Common Equity (%)
-0.38
-12.93
2.97
9.41
11.03
19.88
21.71
22.74
12.73
18.05
24.84
15.62
22.82
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
139
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
968
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
225,251
193,986
205,400

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
17,399
- -
Cash, Cash Equivalents & STI
- -
4,574
- -
Accounts Receivable, Net
- -
2,137
- -
Inventories
- -
10,273
- -
Total Current Liabilities
- -
9,818
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
139
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.81%
13.93%
13.3%
Free Cash Flow
138.07%
5.04%
-129.48%
Net Income, GAAP
60.6%
24.71%
62.02%
Sales/Revenue/Turnover
15.83%
23.64%
32.64%
Total Cash Common Dividend
- -
- -
33.33%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,875
4,080
4,403
4,805
17,133
2026
5,263
5,591
6,116
5,786
22,726
2027
6,828
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-4.72
15.37
12.34
23.3
46.3
2026
22.33
21.69
13.04
17.95
75.01
2027
15.17
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
24
2026
- -
- -
- -
- -
32
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Praveen Rao Akkinepally
Full Time Employees
760
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Manyata Embassy Business Park Bangalore KA India 560045
IPO Date
Jul 30, 1998
Website
astrazeneca.in
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
AstraZeneca Pharma India Limited manufactures, distributes, and markets pharmaceutical products primarily in oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases; key brands include TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex for oncology, Symbicort and Fasenra for respiratory conditions, Brilinta for cardiovascular protection, Farxiga for diabetes and chronic kidney disease, Crestor for cholesterol management, and Koselugo for rare diseases. The company, a subsidiary of AstraZeneca plc (UK) headquartered in Bengaluru, India, and founded in 1979, operates principally within the Indian market, focusing on innovative prescription medicines, research coordination, and clinical trials across these therapeutic areas. Recent developments include a strategic partnership with Sun Pharma to co-promote and distribute sodium zirconium cyclosilicate (SZC) for hyperkalaemia under brand names Lokelma and Gimli, enhancing patient access through combined networks; plans for 15 new product launches through 2025 in oncology, CVRM, respiratory, and rare diseases, some featuring biologics; and resumed revenue growth in FY23 following patent expirations on key drugs like Brilinta and Forxiga.